Below are current clinical trials.14 studies in Colon cancer
(open studies only).
Filter this list of studies by location, status and more.
Scottsdale/Phoenix, Ariz., Rochester, Minn.
In this study, participants with MSI-H or dMMR advanced colorectal carcinoma will be randomly assigned to receive either pembrolizumab or the Investigator's choice of 1 of 6 standard of care (SOC) chemotherapy regimens for the treatment of advanced colorectal carcinoma. The primary study hypothesis is that pembrolizumab will prolong progression-free survival (PFS) compared to current SOC chemotherapy.
The purpose of this study is to measure the quality and quantity of the lifespan in patients who have locally recurrent rectal cancer. It will compare survival rates and quality of life of those who have surgery to those who do not have surgery. It also aims to compare certain other factors, such as whether clear resection margins (i.e. “R0 margins” which are when no evidence of the tumour is found in the biopsy) were achieved and the influence of chemotherapy and radiotherapy.
This randomized phase II study aims to investigate whether the addition of bevacizumab to standard corticosteroid therapy results in greater improvement in symptoms and less treatment-induced symptoms compared with standard corticosteroid therapy for patients with symptomatic brain radionecrosis following radiosurgery. It is hypothesized that the addition of bevacizumab to standard care corticosteroids will reduce treatment-induced toxicities and improve neurologic impairments in patients with brain radionecrosis following radiosurgery for brain metastases.
Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.
This randomized phase II trial studies how well lower-dose compared to standard dose regorafenib works in treating patients with colorectal cancer that has spread from the primary site (place where it started) to other places in the body and does not respond to treatment. Regorafenib may stop the growth of colorectal cancer by blocking the growth of new blood vessels necessary for tumor growth and by blocking some of the enzymes needed for cell growth. It is not yet known whether lower-dose or standard dose regorafenib is more effective in treating patients with colorectal cancer. Clobetasol propionate is a steroid cream that is commonly used to treat a variety of skin conditions and may help prevent hand-foot skin reactions in patients receiving regorafenib.
Aug. 19, 2017
- AskMayoExpert. Colorectal cancer. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2015.
- AskMayoExpert. Colon cancer (surgical management). Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2015.
- Niederhuber JE, et al., eds. Colorectal cancer. In: Abeloff's Clinical Oncology. 5th ed. Philadelphia, Pa.: Churchill Livingstone Elsevier; 2014. http://www.clinicalkey.com. Accessed Jan. 27, 2016.
- Colon cancer. Fort Washington, Pa.: National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed Jan. 27, 2016.
- Distress management. Fort Washington, Pa.: National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed Jan. 27, 2016.
- Colon cancer treatment (PDQ). National Cancer Institute. http://www.cancer.gov/types/colorectal/patient/colon-treatment-pdq. Accessed Jan. 27, 2016.
- Macrae FA. Colorectal cancer: Epidemiology, risk factors and protective factors. http://www.uptodate.com/home. Accessed Feb. 4, 2016.
- Cook AJ. Allscripts EPSi. Mayo Clinic, Rochester, Minn. Jan. 28, 2016.
- O'Keefe SJD, et al. Fat, fibre and cancer risk in African Americans and rural Africans. Nature Communications. 2015;6:6342.
- Moynihan TJ (expert opinion). Mayo Clinic, Rochester, Minn. Feb. 5, 2016.